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Abstract 
Aims:  
To examine the relationship between steatosis quantified by controlled attenuation 
Parameter (CAP) values and glycaemic/metabolic control.  
Methods: 
230 patients, recruited from an Endocrine clinic or primary care underwent routine 
Hepatology assessment, with liver stiffness measurements and simultaneous CAP. 
Multivariable logistic regression was performed to identify potential predictors of Metabolic 
Syndrome (MetS), HbA1c≥7%, use of insulin, hypertriglyceridaemia and CAP≥300dB/m. 
Results:  
Patients were 56.7 ± 12.3 years of age with a high prevalence of MetS (83.5%), T2DM 
(81.3%), and BMI≥40kg/m2(18%). Median CAP score was 344dB/m, ranging from 128 to 
400dB/m. BMI (aOR 1.140 95%CI 1.068-1.216), requirement for insulin  (aOR 2.599 95%CI 
1.212-5.575), and serum ALT (aOR 1.018 95%CI 1.004-1.033) were independently associated 
with CAP≥300dB/m. Patients with CAP interquartile range<40 (68%) had a higher median 
serum ALT level (p=0.029), greater prevalence of BMI≥40kg/m2 (p=0.020) and higher median 
CAP score (p<0.001). Patients with higher CAP scores were more likely to have MetS (aOR 
1.011 95%CI 1.003-1.019), HBA1c≥7 (aOR 1.010 95%CI 1.003-1.016), requirement for insulin 
(aOR 1.007 95%CI 1.002-1.013) and hypertriglyceridemia (aOR 1.007 95%CI 1.002-1.013).  
Conclusions: 
Our data demonstrate that an elevated CAP reflects suboptimal metabolic control. In 
diabetic patients with NAFLD, CAP may be a useful point-of-care test to identify patients at 
risk of poorly controlled metabolic comorbidities or advanced diabetes. 
Keywords: steatosis, metabolic syndrome, controlled attenuation parameter, transient 
elastography, non-alcoholic fatty liver disease 
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Introduction 
The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing in association with 
the widespread presence of metabolic syndrome (MetS), obesity and type 2 diabetes 
(T2DM).1, 2, Diagnosis of NAFLD requires demonstration of steatosis in >5% of hepatocytes in 
the presence of metabolic risk factors and the exclusion of significant alcohol consumption 
(≥20g/day) or other chronic liver diseases.3 In clinical practice, the presence of steatosis is 
usually determined by liver ultrasound, as this method is widely available, simple and 
inexpensive.4 For the detection of moderate to severe steatosis (>33% steatotic 
hepatocytes), liver ultrasound has a sensitivity and specificity of 84.8% and 93.6%, 
respectively.4 Although earlier studies suggested ultrasound had limited ability in detecting 
mild steatosis, more recent studies have determined that using a combination of different 
echographic parameters and a semi-quantitative ultrasonographic score, lesser amounts of 
steatosis (10 – 12.5%) may be detected.5, 6 In view of this ultrasonography remains the first 
line imaging technique investigating NAFLD.3 
More recently the controlled attenuation parameter (CAP) has been evaluated for detection 
and quantitation of steatosis by measuring the degree of ultrasound attenuation during 
simultaneous acquisition of liver stiffness measurements (LSM). This rapid, point-of-care 
test provides a numerical value that correlates with the histological grade of steatosis7, 8 
although discordance has been reported in approximately 15% of cases.9 Performance of 
CAP with the XL probe has shown similar results to the M probe and the same cut-off values 
have been applied in some10 but not all studies.11 The optimal threshold of CAP for the 
detection of steatosis is reported to be around 250dB/m, whereas a cut-off of 280dB/m 
identifies moderate to severe steatosis.9, 10 CAP measurements are only obtained when the 
associated LSM are valid, however additional validity criteria for CAP remain poorly defined. 
Two recent studies found that accuracy of CAP for detection of steatosis was more reliable 
when the interquartile range (IQR) of CAP was <30dB/m11 or <40dB/m.12  
In addition to assessing steatosis, recent studies suggest that CAP also provides information 
about the MetS.13, 14 NAFLD has a complex, bi-directional relationship with the MetS15   and 
previous studies have shown that NAFLD is closely linked with increased BMI, waist 
circumference, hypertriglyceridemia and hyperuricemia16 as well as poor metabolic control 
in type 2 diabetes.17  CAP measurements have been shown to increase progressively with 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
5 
 
the number of MetS components14, 18 prompting speculation that CAP may be an objective 
tool to evaluate the MetS.10, 13, 18 We hypothesized that an elevated CAP score may also 
have a role in identifying patients with type 2 diabetes at risk of suboptimal glycaemic or 
metabolic control and that this relationship may be independent of traditional risk factors 
such as body mass index (BMI) or age.  
Therefore the purpose of this study was to assess the performance of CAP in a cohort of 
NAFLD patients with a high prevalence of T2DM and MetS, and to examine the relationship 
between CAP values, parameters of the MetS and glycaemic/metabolic control. In addition 
we aimed to assess factors associated with the CAP IQR (cIQR) quality indicator 
(cIQR<40dB/m).   
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Methods 
Subjects 
This is a cross-sectional analysis of a prospective study involving patients identified with 
NAFLD between October 2015 and August 2017.  
The source population included (i) consecutive patients attending the Diabetes clinic at the 
Princess Alexandra Hospital, Brisbane, and (ii) all patients referred to secondary care from 
primary care with a history of fatty liver, T2DM or MetS during the study period. All eligible 
patients were invited to attend the liver clinic at the Princess Alexandra Hospital, Brisbane, 
for further clinical assessment. 
Patients were eligible for inclusion if they had attended the liver clinic and had a diagnosis of 
NAFLD defined by demonstration of hepatic steatosis by liver ultrasound in the presence of 
metabolic risk factors and the exclusion of significant alcohol consumption (≥20g/day) or 
other chronic liver diseases (including a prior history of alcohol-related liver disease).3 
Patients were excluded if they had stage 5 chronic kidney disease, renal replacement 
therapy, history of organ transplant or if other causes of hepatic steatosis were suspected. 
Thirty-five per cent of the primary care patients were recruited from a single General 
Practice (Inala Primary Care) that delivers an integrated primary-secondary care diabetes 
service. 
Informed written consent was obtained from each eligible patient. The protocol was 
approved by the Metro South Health and The University of Queensland Human Research 
Ethics Committees (HREC/15/QPAH/301; UQ2015001047).   
Clinical assessment 
Medical history was obtained regarding lifetime alcohol consumption,19 previously 
diagnosed liver disease, other medical conditions, and use of medications.20 Clinical 
assessment included anthropometric measurements (weight, height, girth), laboratory tests 
(routine biochemical, haematological, serological assays), transient elastography and liver 
ultrasound. Definition of obesity based on BMI was adjusted according to ethnicity for 
patients from South Asia (BMI 23-27.4kg/m2 = overweight, BMI 27.5-30.0kg/m2 = Class 1 
obese).21 Metabolic syndrome was defined as central obesity (waist circumference: Europid 
male ≥94 cm, South Asian male ≥90 cm, female ≥80 cm), plus any two of the following 
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four factors: raised fasting plasma glucose or previously diagnosed T2DM, elevated blood 
pressure or treatment of previously diagnosed hypertension, dyslipidaemia (defined as 
raised triglycerides or reduced HDL cholesterol or specific treatment for these lipid 
abnormalities).22  
Transient elastography 
CAP and LSM were performed after a 3 hour fast using FibroScan® technology (Echosens, 
Paris, France) with the standard M or XL probes in accordance with the manufacturer’s 
instructions. Recommended standard FibroScan® operating procedures were followed along 
with adherence to criteria for definition of reliable LSM. The XL probe was used when the 
skin-capsule depth was ≥2.5cm. CAP scores ranging between 100 and 400dB/m were only 
obtained when the associated LSM were valid (IQR-to-median ratio of 10 acquisitions ≤0.3). 
Quality indicators to assist with interpretation of CAP data are still being defined. The cIQR 
was calculated, and factors associated with cIQR<40dB/m12 were determined.  
 The optimal threshold of CAP for the detection of steatosis is reported to be between 246 
and 288dB/m.10, 11 Previous studies have identified moderate/severe steatosis is very likely 
with CAP values >300–310dB/m (positive predictive value 80%).10, 23 In accordance with 
these CAP thresholds, patients were separated into 3 groups: low CAP<250dB/m, 
intermediate 250–300dB/m and high >300dB/m.10 
Liver biopsy was performed in a proportion of patients with advanced fibrosis or cirrhosis 
based on the FibroScan® examination, discordant results of investigations for cirrhosis, or 
interest in participating in a clinical therapy trial. Liver histology was assessed by a single 
experienced pathologist (ADC) who was blinded to the clinical data and histological scoring 
was performed according to the system of Kleiner et al.24  
Data analysis 
Participant socio-demographic and clinical characteristics were described using frequency 
and percentage for categorical variables, mean and standard deviation (SD) for continuous 
data normally distributed, and median and IQR for non-normally distributed data. 
Correlation between continuous variables was assessed using Pearson correlation or 
Spearman’s rho correlation (non-parametric case). The univariate relationship between two 
categorical variables was assessed using Pearson’s Chi-square test or Fisher’s exact test 
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where appropriate. Post-hoc testing was conducted using a partitioning Chi-square when 
required.  The comparison of a continuous variable between two groups was tested using 
the independent T-test or Mann-Whitney U test (non-parametric). When comparing more 
than 2 groups one-way ANOVA or Kruskal-Wallis test (non-parametric case) was used. 
Univariate logistic regression was performed to identify potential predictors of MetS, 
HbA1c≥7% (53mmol/mol), requirement for insulin, hypertriglyceridaemia and 
CAP≥300dB/m. All variables from the univariate analysis with p-values less than 0.2 were 
included in a multiple logistic regression model with backward stepwise selection to identify 
factors influencing the outcome. Odds ratios (OR), adjusted odds ratios (aOR) and 95% 
confidence interval (CI) were reported. All p values were 2-sided and statistical significance 
was set at alpha=0.05. Data analysis was conducted using SPSS Inc version 24.0 (College 
Station TX: StatCorp LP; 2013). 
Results  
Characteristics of the study population 
Of the 252 patients with NAFLD reviewed in the Hepatology Clinic, 230 (91.3%) had reliable 
LSM by either the XL probe (76.5%) or M probe (23.5%) and were included in the CAP 
examination. 
The mean age of subjects was 56.7±12.3 years and 54.8% were male. The majority (77.0%) 
were Caucasian, with a mean BMI of 34.3±7.8kg/m2 and mean girth 115.4±18.0cm. Overall, 
patients had a high prevalence of MetS (83.5%), T2DM (81.3%), and more than 18% of the 
cohort had ≥class 3 obesity (BMI≥40 kg/m2). Median LSM was 6.1kPa with a range from 2.5 
to 63.9kPa. 
Factors associated with CAP score 
The median CAP score was 344dB/m with a range from 128 to 400dB/m. 74.3% of patients 
had a CAP≥300dB/m consistent with moderate/severe steatosis. The demographic and 
clinical characteristics of the cohort according to CAP threshold category are summarized in 
Table 1. There was an increase in BMI, girth and prevalence of MetS with increasing CAP 
score category (p<0.001), along with increasing prevalence of suboptimal glycaemic control 
(HbA1c≥7%, p=0.025), hypertriglyceridemia (p=0.012) and requirement for insulin (p=0.006). 
Although LSM increased across the CAP categories (p<0.001), the median values were low. 
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Liver histology was available for 47 patients and showed grade 1 steatosis in 11 patients, 
grade 2 in 8, grade 3 in 28. All patients with grade 2 or 3 (moderate/severe) steatosis on 
liver histology had CAP≥300dB/m.   
Multivariable logistic regression analysis was used to determine the factors associated with 
CAP≥300dB/m compared to CAP<300dB/m. The final model identified BMI, LSM, 
requirement for insulin, serum ALT level and presence of dyslipidaemia as significant factors 
influencing CAP ≥300 dB/m. BMI, requiring insulin, and serum ALT remained independently 
associated with CAP≥300dB/m (Table 2). 
Influence of CAP on presence of the MetS, glycaemic control and dyslipidaemia 
Multivariable logistic regression analysis was used to determine the factors associated with 
presence of the MetS, glycaemic control (specifically HbA1c≥7% and requirement for insulin) 
and hypertriglyceridemia (defined as serum triglycerides ≥1.7mmol/L) (Table 3). These 
analyses identified that, independent of BMI and age, for every 1dB/m increase in CAP 
score, there was a 1.011-fold increase (95%CI 1.003-1.019; p=0.009) in risk of having the 
MetS. Patients with a higher CAP were more likely to have a HbA1c≥7% (aOR 1.007 95%CI 
1.002-1.013), and require insulin (aOR1.010 95%CI 1.002-1.013). Multivariable logistic 
regression analysis also identified CAP as a significant factor influencing the presence of 
hypertriglyceridaemia, however BMI, age and gender were included in the model as 
variables of interest. For every 1 dB/m increase in CAP score, there was a 1.007-fold 
increase (95%CI 1.002-1.013) in risk of having hypertriglyceridaemia.  
Factors associated with CAP IQR  
The relationship between cIQR and CAP score is illustrated in Figure 1a. In contrast to LSM 
(Figure 1b), cIQR had a moderate inverse correlation with CAP (Spearman’s Rho=-0.467, 
p<0.001). Of the 230 patients with reliable LSM, 157 (68.3%) had CAP scores with 
cIQR<40dB/m. Demographic and clinical characteristics according to CAP scores with cIQR< 
or ≥40dB/m are summarized in Table 4. Patients with cIQR<40 (68%) had a higher 
prevalence of BMI≥40kg/m2 (p=0.020), higher median serum ALT level (p=0.029), and higher 
median CAP score (p<0.001). 
Multivariable logistic regression analysis used to determine the factors associated with 
CAP≥300dB/m compared to CAP<300dB/m was repeated in those patients with cIQR<40 
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(N=157). The final model obtained identified BMI (aOR1.189 95%CI 1.086-1.298), and 
requiring insulin (aOR4.319 95%CI 1.354-13.778), as significant factors influencing 
CAP≥300dB/m.  
 
Discussion 
In this cohort of patients with NAFLD and a high prevalence of T2DM and MetS, CAP was 
independently associated with presence of the MetS, and with the severity of metabolic 
abnormalities. These results support previous studies which demonstrated that presence of 
the MetS was independently associated with elevated CAP score, along with insulin 
resistance and increased serum uric acid.14 In addition, our study showed that increasing 
CAP was associated with poorer diabetic control (defined by HbA1c≥7%, increasing number 
of diabetic medications prescribed, and requiring insulin) and hypertriglyceridemia. This 
information may add value to results provided by the clinical, laboratory and imaging 
studies performed routinely in patients with NAFLD, and suggests that CAP may be a useful 
surrogate marker of more advanced diabetes or metabolic disease duration.  
The accuracy of CAP for detection of steatosis ≥10% and differentiation between steatosis 
grades at least 2 grades apart, is reported to be good, and is independent of histological 
fibrosis stage, activity grade and liver disease etiology.8, 25-27 However clinical use of this tool 
has been hampered by the lack of validity criteria for CAP and knowledge of the factors 
associated with inaccurate CAP measurements. For LSM, the most important validity 
indicator is the IQR-to-median ratio.28 The IQR of LSM increases with higher median LSM 
values and therefore normalization of IQR to the median LSM is necessary to allow its use as 
a quality indicator across a broad range of LSM.12 In contrast, we and others12 have shown 
that cIQR decreases with increasing median CAP value, possibly related to the relatively high 
number of patients scoring close to the maximum CAP value of 400dB/m. Wong and 
colleagues showed that the accuracy of CAP for the diagnosis of fatty liver by M probe is 
lower if the cIQR is ≥40dB/m.12 In their derivation cohort, the area under the receiver-
operating characteristic curve (AUROC) for CAP diagnosis of fatty liver was 0.86, 0.89 and 
0.76 in patients with cIQR of <20, 20-39 and ≥40dB/m, respectively, and was similar in a 
validation cohort of 414 patients.12 Similarly, in a smaller study of 119 subjects who 
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underwent MRI-PDFF, the diagnostic accuracy of CAP increased when the cIQR was 
<30dB/m (AUROC 0.92 and 0.70 for cIQR < or ≥30dB/m respectively).11 
Compared with LSM, the proportion of patients with CAP measurements that meet 
proposed validity criteria is lower. In our study 68% patients with reliable LSM had 
cIQR<40dB/m. This proportion is similar to previous studies in which 67% of a derivation 
cohort and 66% of a validation cohort had cIQR<40dB/m12 and 50% of another cross-
sectional study had cIQR<30dB/m.11  In our cohort, patients with cIQR<40dB/m had a higher 
median serum ALT level and a higher prevalence of BMI≥40kg/m2, possibly reflecting more 
severe steatosis and a higher CAP score. There were no other differences in clinical or 
demographic factors between patients with and without cIQR<40dB/m, consistent with 
reports that the usual factors affecting LSM performance (such as high liver enzymes and 
severe obesity), have little impact on CAP accuracy.12  Importantly, the factors associated 
with CAP≥300dB/m were comparable in both the smaller cohort with cIQR<40dB/m and the 
overall patient cohort. Similarly, use of cIQR cut-off <40dB/m did not appear to impact the 
relationship between CAP score and presence of the MetS. Further studies are necessary to 
determine whether cIQR cut-offs have a clinically relevant impact on diagnostic accuracy or 
grading of steatosis severity, and if so, what strategies may increase the proportion of 
patients with a valid cIQR. 
Since CAP has been shown to accurately identify the extent of steatosis due to various 
causes,9, 18, 29, 30 it is not surprising that CAP has been shown to be independently associated 
with metabolic risk factors for the development of NAFLD, including increasing BMI, girth 
and presence of the MetS, in the present study as in foregoing reports. As liver histology 
was only available in a small number of patients, we were unable to determine if the 
association between these factors and CAP was independent of steatosis severity. However 
in a recent study of patients with fatty liver (diagnosed by liver biopsy) and healthy controls 
with intrahepatic triglyceride content <5% (by proton-magnetic resonance spectroscopy), 
obesity was associated with higher CAP values following adjustment for grade of steatosis.12 
Patients with BMI≥30kg/m2 had higher CAP values (M probe) than those with BMI<30kg/m2 
at each steatosis grade.12 Similarly, in a study using the XL probe, a high CAP was positively 
associated with waist circumference in multivariate analysis.10 The mechanism remains 
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unclear but may be due to increased subcutaneous fat and skin capsular distance 
attenuating the ultrasonic signals,31 and further assessment using the XL probe is warranted.  
Importantly, we showed that increasing CAP scores are associated with suboptimal 
glycaemic control and treatment escalation in patients with NAFLD, independently of BMI. 
These data confirm previous studies showing that a high CAP was independently associated 
with serum triglyceride level,10, 32  fasting plasma glucose14, 32 and elevated HOMA-IR 
score.14 Although the severity of steatosis does not appear to impact liver disease 
progression in NAFLD, cardiovascular diseases are the leading cause of morbidity and 
mortality in these patients, and optimal diabetic control reduces the long term risk of 
cardiovascular events.33 In a recent study of 4,282 patients (1,542 with NAFLD), neither the 
presence nor the severity of steatosis as measured by CAP predicted liver-related events, 
non-hepatocellular carcinoma or cardiovascular events over a median follow-up period of 
26 months.34 In contrast to this short-term study, a 10 year follow-up study of patients with 
NAFLD (n=91) and matched controls (n=182) showed that steatosis (hazard ratio 1.99, 95% 
CI 1.01 – 3.94) and presence of plaques (hazard ratio 5.08, 95% CI 2.56 – 10.96) were the 
strongest predictors by multivariate analysis for cardiovascular events.35 In addition, grade 
of steatosis (evaluated by liver histology at enrolment), and liver enzyme levels were higher 
in NAFLD patients who developed cardiovascular events.35 It is also unknown whether an 
increased CAP score is a predictor of response to bariatric surgery. Currently patients with 
poorly controlled diabetes and obesity are offered radical bariatric surgery with ~60% 
achieving diabetes remission. A better predictor of those who develop remission and the 
ability to cease insulin would be beneficial. 
Strengths of our study include the prospective recruitment of unselected “real-world” 
subjects from both diabetes and primary care clinics. Our findings are further evidence for 
NAFLD as a systemic condition,36 however the mechanisms underlying the association 
between CAP and metabolic derangement remain to be clarified. The study has a number of 
limitations. In particular, liver biopsy was only performed in a subset of the patients who 
were selected based on increased likelihood of advanced disease or patient interest in 
participating in clinical therapeutic trials. Due to the lack of availability of magnetic 
resonance imaging37 or semi-quantitative ultrasonographic indices38 we were unable to 
validate the CAP measurements. This was a small single-centre study with preferential 
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recruitment of patients with MetS and diabetes. Therefore, our findings may not be 
representative of the wider population with NAFLD.  
Our data illustrate an association between CAP score, poor glycaemic control, requirement 
for insulin therapy and hypertriglyceridaemia. CAP is a rapid, point-of-care test providing a 
numerical value that correlates with the histological grade of steatosis7, 8, 26, 27  and with the 
severity of metabolic abnormalities14, 18. When assessing a diabetic patient with NAFLD, a 
higher CAP score may immediately identify patients at risk of poorly controlled metabolic 
comorbidities or advanced diabetes. The value of CAP in predicting liver and overall clinical 
outcomes will require ongoing prospective evaluation, as CAP technology has only been 
available for a short period of time. Nevertheless, our data demonstrate that an elevated 
CAP score reflects suboptimal metabolic control.   
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 Table 1: Demographic and clinical characteristics of the cohort according to CAP threshold category 
 
†
Data presented continuously (median and interquartile range) and analysed using the Kruskal-Wallis test
 ‡
Data presented categorically and analysed using Pearson’s χ
2
. 
§
Data presented 
categorically and analysed using the Fisher’s Exact test.  
 
Low <250 dB/m 
N=24 
Intermediate 250-299 dB/m 
N=35 
High ≥300 dB/m 
N=171 
P value 
Age (years)† 55.5 (53.0-66.3) 61.0 (50.0-68.0) 58.0 (49.0-65.0) 0.605 
Male Gender, N (%)‡ 13 (54.2) 17 (48.6) 96 (56.1) 0.713 
BMI (kg/m2)† 25.6 (24.0-29.9) 30.9 (29.3-34.0) 35.0 (30.4-39.5) <0.001 
Girth (cm)† 94.0 (88.5-100.8) 111.0 (102.0-117.0) 120.0 (107.0-131.0) <0.001 
Type 2 Diabetes, N (%)‡ 19 (79.2) 26 (74.3) 142 (83.0) 0.462 
Metabolic syndrome, N (%)‡ 13 (54.2) 29 (82.9) 150 (87.7) <0.001 
HbA1c ≥7%, N (%)‡ 9 (37.5) 15 (42.9) 104 (60.8) 0.025 
Number of diabetic 
medications,  
N (%)§ 
0 7 (29.2) 12 (34.3) 41 (24.0) 
0.277 1-2 15 (62.5) 17 (48.6) 87 (50.9) 
3+ 2 (8.2) 6 (17.1) 43 (25.1) 
Requirement for Insulin, N (%) 5 (20.8) 8 (22.9) 78 (45.6) 0.006 
Dyslipidaemia§, N (%) 22 (91.7) 31 (88.6) 165 (96.5) 0.077 
Triglycerides (mmol/L)† 1.4 (0.9-2.0) 1.7 (1.0-2.4) 1.9 (1.4-2.8) 0.012 
Hypertension‡, N (%) 14 (58.3) 26 (74.3) 128 (74.9) 0.229 
OSA†, N (%) 2 (8.3) 11 (31.4) 52 (30.4) 0.062 
Liver tests† 
ALT (IU/ml) 22.0 (19.0-36.0) 27.0 (18.0-36.0) 34.0 (24.0-57.0) 0.002 
AST (IU/ml) 19.5 (15.3-28.8) 18.0 (14.0-28.0) 25.0 (18.0-37.3) 0.010 
GGT (IU/ml) 21.5 (14.3-69.0) 24.0 (14.3-55.0) 37.0 (23.0-63.0) 0.021 
Steatosis Grade§ 
1 2 (100) 2 (100) 7 (16.3) 
0.009 2 0 (0) 0 (0) 8 (18.6) 
3 0 (0) 0 (0) 28 (65.1) 
LSM (kPa)† 4.4 (3.6-6.2) 5.2 (4.4-6.3) 6.8 (5.1-11.3) <0.001 
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Table 2: Factors associated with CAP < or ≥ 300 dB/m 
 
†
All variables adjusted for BMI, LSM, requirement for insulin, serum ALT and presence of dyslipidaemia unless otherwise 
reported. 
‡
Adjusted for LSM, requirement for insulin, serum ALT and presence of dyslipidaemia. 
§
Adjusted for LSM,  
requirement for insulin, serum ALT and presence of dyslipidaemia.  
 Univariate 
P value 
Univariate 
Odds Ratio (95% CI) 
Adjusted 
P value 
Adjusted  
Odds Ratio† (95% CI) 
Age (years) 0.337 0.988 (0.964-1.013) 0.739 0.995 (0.967-1.026) 
Male Gender 0.482 1.237 (0.684-2.239) 0.483 1.278 (0.644-2.535) 
BMI (kg/m2) <0.001 1.173 (1.101-1.250) <0.001 1.140 (1.068-1.216) 
BMI 
category 
normal <0.001  0.003  
Cat 1-2 0.001 3.094 (1.627-5.882) 0.027‡ 2.205 (1.094-4.443)‡ 
Cat 3 plus 0.001 35.469 (4.614-272.532) 0.003‡ 25.537 (3.005-217.024)‡ 
Girthb (cm) <0.001 1.058 (1.035-1.081) <0.001§ 1.046 (1.021-1.072)§ 
Diabetes 0.252 1.523 (0.741-3.132) 0.830 0.902 (0.352-2.310) 
Hypertension 0.293 1.414 (0.741-2.698) 0.139 0.539 (0.238-1.222) 
Metabolic syndrome 0.004 2.891 (1.400-5.971) 0.794 1.138 (0.431-3.003) 
OSA 0.220 1.546 (0.770-3.103) 0.362 0.670 (0.284-1.584) 
HbA1c ≥7% 0.008 2.264 (1.238-4.139) 0.507 1.291 (0.607-2.746) 
Requirement for Insulin 0.002 2.968 (1.496-5.889) 0.014 2.599 (1.212-5.575) 
Dyslipidaemia 0.058 3.113 (0.963-10.062) 0.081 3.892 (0.847-17.886) 
ALT (IU/ml) 0.017 1.017 (1.003-1.029) 0.018 1.018 (1.004-1.033) 
AST (IU/ml) 0.027 1.023 (1.003-1.045) 0.593 0.989 (0.951-1.029) 
Albumin (g/L) 0.908 1.005 (0.920-1.098) 0.083 1.105 (0.987-1.237) 
Platelets (x109) 0.613 0.999 (0.994-1.003) 0.463 0.998 (0.992-1.004) 
LSM (kPa) 0.002 1.188 (1.066-1.324) 0.146 1.068 (0.977-1.166) 
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Table 3: Factors identified by multivariable backward stepwise logistic regression associated with presence of the metabolic syndrome, 
glycaemic control, use of insulin and dyslipidaemia 
 
 Presence of Metabolic syndrome HbA1c ≥7 Use of insulin Hypertriglyceridemia 
aOR (95%CI) P value aOR (95%CI) P value aOR (95%CI) P value aOR (95%CI) P value 
CAP (db/m) 1.011 (1.003-1.019) 0.009 1.007 (1.002-1.013) 0.012 1.010 (1.003-1.016) 0.006 1.007 (1.002-1.013) 0.011 
Age (years) 1.091 (1.050-1.133) <0.001 - - - - 1.003 (0.980-1.026) 0.804 
BMI (kg/m2) 1.105 (1.018-1.200) 0.018 - - 0.959 (0.915-1.019) 0.086 0.995 (0.954-1.038) 0.815 
Gender - - 1.739 (0.955-3.166) 0.070 - - 0.983 (0.560-1.724) 0.951 
Hypertension - - 3.163 (1.606-6.229) 0.001 2.348 (1.019-5.410) 0.045 - - 
Albumin (g/L) 0.869 (0.758-0.997) 0.046 0.850 (0.767-0.943) 0.002 0.798 (0.711-0.895) <0.001 - - 
ALT (IU/ml) - - 0.989 (0.979-1.000) 0.043 0.988 (0.976-1.001) 0.072 - - 
On treatment for 
dyslipidaemia 
- - - - 2.976 (1.412-6.273) 0.004 - - 
LSM (kPa)  - - - - 1.038 (0.999-1.079) 0.056 - - 
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Table 4: Demographic and clinical characteristics of the cohort according to CAP IQR < or ≥40 
†
Data presented continuously (median + range) and analysed using the Mann-Whitney U test 
‡
Data presented categorically 
and analysed using Pearson’s Chi Squared. 
§
Data presented categorically and analysed using the Fisher’s Exact test. 
¶
Data 
presented continuously and analysed using an independent T test.  
 
 
  
CAP IQR <40 
N=157 
CAP IQR  ≥40 
N=73 
p  value 
 
Age (years)† 57 (49-64) 61 (52-70) 0.063 
Male Gender, N (%)‡ 89 (56.7) 37 (50.7) 0.395 
Caucasian‡ 121 (77.1) 56 (76.7) 0.952 
BMI (kg/m2)† 33.0 (29.3-39.3) 31.8 (29.0-36.2) 0.172 
BMI ≥40.0 (kg/m2), N (%)‡ 35 (22.3) 7 (9.6) 0.020 
Waist Circumference (cm)¶ 117±19 113±16 0.106 
T2DM, N(%)‡ 130 (82.8) 57 (78.1) 0.393 
Metabolic Syndrome, N (%)‡ 133 (84.7) 59 (80.8) 0.459 
ALT (IU/mL)† 34 (23-55) 29 (19-51) 0.029 
AST (IU/mL)† 25 (18-37) 21 (15-36) 0.145 
GGT( IU/mL)† 37 (22-63) 27 (18-55) 0.064 
Platelets (x109)¶ 250±63 240±67 0.329 
Serum Albumin (g/L)† 41 (39-43) 42(40-44) 0.469 
HbA1c ≥7, N (%)‡ 93 (59.2) 35 (47.9) 0.109 
LSM (kPa)† 6.2 (4.9-8.9) 6.1 (4.4-10.2) 0.936 
LSM IQR†  0.7 (0.4-1.0) 0.7 (05-1.3) 0.395 
LSM  ≥8.2, N (%)‡ 47 (29.9) 25 (34.2) 0.512 
Quality of 
LSM 
Reading§ 
Poor 3 (1.9) 1 (1.4) 
0.838 Reasonable 31 (19.7) 17 (23.3) 
Good 123 (78.3) 55 (75.3) 
CAP (dB/m)† 355 (319-390) 308 (267-352) <0.001 
XL Probe, N (%)‡ 112 (71.3) 64 (87.7) 0.007 
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Figure Legends: 
Figure 1: The relationship between a) CAP and CAP IQR and b) LSM and LSM IQR 
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Highlights:  
Controlled attenuation parameter in NAFLD identifies risk of suboptimal glycaemic and metabolic 
control 
 Patients with an elevated CAP Score were more likely to have metabolic syndrome. 
 Elevated CAP scores reflect suboptimal metabolic control in terms of elevated HbA1c, 
requirement for insulin and hypertriglyceridaemia. CAP measurement may be a useful 
surrogate marker of more advanced diabetes or metabolic disease duration. 
 Validity criteria for CAP measurements remain poorly defined. However our data did not 
identify any differences when the CAP interquartile range <40 or ≥40, in factors 
independently predicting the likelihood of having a high CAP score. 
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